Zak Mir takes a charting look at S&P 500, Nasdaq 100, AEON, Apollomics, Femasys, INVO, Lobo, NextCure, Personalis, Real Messenger, REE, and Sensei.
In this update I take a charting look at the S&P 500, Nasdaq 100 and a basket of individual names showing constructive set-ups. This piece summarises the key levels, the setups I’m watching, and where I expect a number of stocks to trade over the coming weeks. The aim is simple: identify the trend, respect the moving averages and use RSI behaviour to time entries and targets.
As always, do your own research and treat these as chart-based observations rather than hard recommendations.
Quick outline
- Market overview — S&P 500 and Nasdaq 100: trend channels, RSI and key support/resistance.
- Stock-by-stock watchlist: AEON, Apollomics, Femasys, INVO, Lobo, NextCure, Personalis, Real Messenger, REE, Sensei.
- Trade management notes — moving averages, RSI signals and targets with expected timeframes.
Market overview
S&P 500
We’re being told to fear a crash, but so far that hasn’t materialised. The chart shows a double fade of the RSI sitting in the low 50s — one of the more dangerous setups because it suggests the market is tipping toward the downside. Still, price remains within the rising trend channel that began in April and is holding above post‑September support.
- Key support: last week’s low around 6550 — as long as there’s no end‑of‑day close back below this, the bias is to buy dips and sell strength.
- Risk: the RSI weakness means caution; if price closes below 6550, reassess the trade plan.
Nasdaq 100
The Nasdaq is near the highs towards 25,000 and has pulled back but remains inside its rising trend channel and above the 24,000 level. RSI is still above neutral 50 overall despite a couple of short peaks in the upper 50s.
- Upside target: a continuation toward about 25,800 while the channel holds.
- Downside risk: if the channel breaks, the favoured area for a pullback is around 23,800 (previous August / early September resistance).
- Plan: no panic yet — stay long within the channel, manage risk if key midlines are breached.
Individual stocks I’m watching
Below are the setups I’m tracking. For each name I note the trigger level, the moving‑average context and my target/timeframe assumptions.
AEON Biopharma, Inc. (AEON)
- Shares gapped up earlier this month and continue to push higher within a rising channel.
- Target: the top of the channel near $2.20 — likely by the end of next month given the current momentum.
- Support: recent support around $1.05 ; short‑term resistance-turned-support at $1.22 may be tested.
Apollomics, Inc. (APLM)
- We’ve already hit the third target, which is always pleasing. That was around $35 .
- Next leg: if Apollomics clears the recent resistance near $34–35 , the next meaningful target is in the low‑to‑mid $50s (old resistance/support on the way down, $52 ).
- Risk management: staying above the upper 20s on pullbacks keeps the bullish case intact.
Femasys Inc. (FEMY)
- After touching the top of its channel, shares pulled back to test the 50‑day moving average (around $0.50 at the time of the update).
- Scenario: as long as we remain above recent broken resistance near $0.68 , a retest of the channel top around $0.93 — or possibly the 200‑day line ($0.97 ) — is plausible.
INVO Fertility, Inc. (IVF)
- INVO is trying to regroup after earlier weakness. The crucial level is the 50‑day moving average.
- Trigger: a clean hold and push above the 50‑day (around $1.13 ) supports a run toward the top of the rising channel, roughly $2.75 , perhaps by the end of next month.
- Key: keep above the 50‑day MA to maintain the bullish thesis.
Lobo Technologies Ltd. (LOBO)
- Clear rising trend channel in place.
- Target: top of the channel near $1.57 while price stays above the 200‑day moving average ($0.92 ).
- RSI has shown a couple of rebounds near neutral 50 — supportive for continuation.
NextCure, Inc. (NXTC)
- Another rising trend channel set-up. The pattern started with multiple RSI 50 rebounds which is constructive.
- Target: the channel top around $11.60
- Support: above recent broken resistance just above $7 .
Personalis, Inc. (PSNL)
- Sharp rising channel with a bull‑flag breakout. The breakout level to watch is around $8.90 .
- Target: a move toward $12 — possibly by the end of this month if momentum continues.
Real Messenger Corporation (RMSG)
- The chart has seen a severe move through the 200‑day line previously, but the 15‑day and 200‑day lines are now rising.
- Current pivot: clearing the 50‑day line (around $2.75 ) is constructive.
- Target: a retest of the nominal top of the channel, as high as $4.30 , by the end of this month if the recovery holds.
REE Automotive Ltd. (REE)
- Another rising channel name.
- Target: the top of the channel near $2.40 while shares stay above recent broken resistance at about $1.14 .
Sensei Biotherapeutics, Inc. (SNSE)
- Shares have already cleared the first target at the top of the channel ( $16 ).
- Next target: an upper parallel of the rising trend channel that dates back to December, as high as $23 , by the end of next month.
- This rally began with multiple RSI rebounds off the 50 level — bullish structure as long as Sensei remains above the old March peak ($15–20 reference in the chart).
Trade management and final thoughts
My approach is straightforward: respect the trend channel, use moving averages (50‑ and 200‑day) as guides and watch RSI action around neutral 50 for entries or warnings. Most of the names above are conditional — they work while key levels hold. If those levels break, tighten stops or reassess the position rather than forcing a thesis.
““Buy the dip and sell into strength” — a simple mantra, but one that still works when you align entries with moving averages and RSI confirmation.”
I’ll be posting more updates over the weekend — keep an eye on the charts and manage your risk accordingly.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
